Hope Tribune

Multiple System Atrophy Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Neuramedy Co.,Ltd, ProMIS

 Breaking News
  • No posts were found

Multiple System Atrophy Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Neuramedy Co.,Ltd, ProMIS

October 30
10:34 2023
Multiple System Atrophy Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies,  Mechanism of Action, Route of Administration by DelveInsight | Neuramedy Co.,Ltd, ProMIS
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Multiple System Atrophy pipeline constitutes 20+ key companies continuously working towards developing 20+ Multiple System Atrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Multiple System Atrophy Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Multiple System Atrophy Market.

 

The Multiple System Atrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Multiple System Atrophy Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Multiple System Atrophy treatment therapies with a considerable amount of success over the years. 
  • Multiple System Atrophy companies working in the treatment market are Neuramedy Co.,Ltd, ProMIS Neurosciences, Enterin Inc., Nippon Chemiphar, CORESTEM, Inc, Brain Neurotherapy Bio, Inc., Kainos Medicines, Alterity Therapeutics, H. Lundbeck A/S, Biohaven, Ltd, Selecta Biosciences Inc, Ionis Pharmaceuticals, Inc, and others, are developing therapies for the Multiple System Atrophy treatment 
  • Emerging Multiple System Atrophy therapies in the different phases of clinical trials are- NM-402, PMN442, ENT-01, NC-2500, CS10BR05, AAV2-GDNF, KM-819, ATH434, Lu AF82422, Verdiperstat, Ampreloxetine, ION464, and others are expected to have a significant impact on the Multiple System Atrophy market in the coming years.   
  • In May 2023, Ampreloxetine has been given Orphan Drug Designation (ODD) status by the US Food and Drug Administration (FDA) to treat symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA). This announcement was made by Theravance Biopharma, Inc.
  • In March 2023, In order to treat symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy, Theravance Biopharma started a Phase III, multicenter, randomized withdrawal and long-term extension study with ampreloxetine.
  • In February 2023, In order to move on with the ATH434 Phase II Clinical Trial, Alterity Therapeutics has been granted regulatory authorization in France and Austria. The French National Agency for the Safety of Medicine and Health Products and the Austrian Federal Office for Safety in Healthcare have authorized a biotechnology business to carry out its Phase II clinical study for ATH434 in Multiple System Atrophy (MSA). One really crippling Parkinsonian condition that is rare is MSA.
  • In December 2022, The MSA alliance, the premier nonprofit provider of financing for MSA research worldwide, declared that it had invested over USD 3.5 million in MSA research funding overall since 2013. Seven new clinical, preclinical, biomarker, and pathogenesis research at various institutions across the globe were funded by the MSA coalition.

 

Multiple System Atrophy Overview

A rare condition known as multiple system atrophy (MSA) may impact 15,000 to 50,000 Americans, including members of all racial groups. There is no recognized cause of Multiple System Atrophy. Most occurrences are sporadic, which means that they happen at random.

 

Get a Free Sample PDF Report to know more about Multiple System Atrophy Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/multiple-system-atrophy-msa-pipeline-insight

 

Emerging Multiple System Atrophy Drugs Under Different Phases of Clinical Development Include:

  • NM-402: Neuramedy Co.,Ltd
  • PMN442: ProMIS Neurosciences
  • ENT-01: Enterin Inc.
  • NC-2500: Nippon Chemiphar
  • CS10BR05: CORESTEM, Inc
  • AAV2-GDNF: Brain Neurotherapy Bio, Inc.
  • KM-819: Kainos Medicines
  • ATH434: Alterity Therapeutics
  • Lu AF82422: H. Lundbeck A/S
  • Verdiperstat: Biohaven, Ltd
  • Ampreloxetine: Selecta Biosciences Inc
  • ION464: Ionis Pharmaceuticals, Inc

 

Multiple System Atrophy Route of Administration

Multiple System Atrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Inhalation
  • Inhalation/Intravenous/Oral
  • Intranasal
  • Intravenous
  • Intravenous/ Subcutaneous
  • NA
  • Oral
  • Oral/intranasal/subcutaneous
  • Parenteral
  • Subcutaneous

 

Multiple System Atrophy Molecule Type

Multiple System Atrophy Products have been categorized under various Molecule types, such as

  • Antibody
  • Antisense oligonucleotides
  • Immunotherapy
  • Monoclonal antibody
  • Peptides
  • Protein
  • Recombinant protein
  • Small molecule
  • Stem Cell
  • Vaccine

 

Multiple System Atrophy Pipeline Therapeutics Assessment

  • Multiple System Atrophy Assessment by Product Type
  • Multiple System Atrophy By Stage and Product Type
  • Multiple System Atrophy Assessment by Route of Administration
  • Multiple System Atrophy By Stage and Route of Administration
  • Multiple System Atrophy Assessment by Molecule Type
  • Multiple System Atrophy by Stage and Molecule Type

 

DelveInsight’s Multiple System Atrophy Report covers around 20+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Multiple System Atrophy product details are provided in the report. Download the Multiple System Atrophy pipeline report to learn more about the emerging Multiple System Atrophy therapies

 

Some of the key companies in the Multiple System Atrophy Therapeutics Market include:

Key companies developing therapies for Multiple System Atrophy are – Biogen, Corestem, Inc., Asklepios BioPharmaceutical, Inhibikase Therapeutics, RETROTOPE, Modag, AC Immune, Vaxxinity, Neuramedy, ProMIS Neurosciences, FAScinate Therapeutics, Theravance Biopharma, Ionis Pharmaceuticals, Inc., Biohaven Pharmaceuticals, Lundbeck A/S, Alterity Therapeutics, Brain Neurotherapy Bio, Inc., Wren Therapeutics, Blade Therapeutics, Stealth BioTherapeutics, and others.

 

Multiple System Atrophy Pipeline Analysis:

The Multiple System Atrophy pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Multiple System Atrophy with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple System Atrophy Treatment.
  • Multiple System Atrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Multiple System Atrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Multiple System Atrophy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Multiple System Atrophy drugs and therapies

 

Multiple System Atrophy Pipeline Market Drivers

  • Increased Awareness and Diagnosis, rising Genetic Research Activities are some of the important factors that are fueling the Multiple System Atrophy Market.

 

Multiple System Atrophy Pipeline Market Barriers

  • However, ethical and Practical Challenges in clinical trials, lack of Early and Specific Diagnostic Biomarkers, poor Understanding of Disease Mechanism and other factors are creating obstacles in the Multiple System Atrophy Market growth.

 

Scope of Multiple System Atrophy Pipeline Drug Insight    

  • Coverage: Global
  • Key Multiple System Atrophy Companies: Neuramedy Co.,Ltd, ProMIS Neurosciences, Enterin Inc., Nippon Chemiphar, CORESTEM, Inc, Brain Neurotherapy Bio, Inc., Kainos Medicines, Alterity Therapeutics, H. Lundbeck A/S, Biohaven, Ltd, Selecta Biosciences Inc, Ionis Pharmaceuticals, Inc, and others
  • Key Multiple System Atrophy Therapies: NM-402, PMN442, ENT-01, NC-2500, CS10BR05, AAV2-GDNF, KM-819, ATH434, Lu AF82422, Verdiperstat, Ampreloxetine, ION464, and others
  • Multiple System Atrophy Therapeutic Assessment: Multiple System Atrophy current marketed and Multiple System Atrophy emerging therapies
  • Multiple System Atrophy Market Dynamics: Multiple System Atrophy market drivers and Multiple System Atrophy market barriers 

 

Request for Sample PDF Report for Multiple System Atrophy Pipeline Assessment and clinical trials

 

Table of Contents

1. Multiple System Atrophy Report Introduction

2. Multiple System Atrophy Executive Summary

3. Multiple System Atrophy Overview

4. Multiple System Atrophy- Analytical Perspective In-depth Commercial Assessment

5. Multiple System Atrophy Pipeline Therapeutics

6. Multiple System Atrophy Late Stage Products (Phase II/III)

7. Multiple System Atrophy Mid Stage Products (Phase II)

8. Multiple System Atrophy Early Stage Products (Phase I)

9. Multiple System Atrophy Preclinical Stage Products

10. Multiple System Atrophy Therapeutics Assessment

11. Multiple System Atrophy Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Multiple System Atrophy Key Companies

14. Multiple System Atrophy Key Products

15. Multiple System Atrophy Unmet Needs

16 . Multiple System Atrophy Market Drivers and Barriers

17. Multiple System Atrophy Future Perspectives and Conclusion

18. Multiple System Atrophy Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Categories